Live · Q2 2026·Network of trade 8 active spots·FX ECB · 31 May 19:49 CET·Updated hourlyportal v3 · 31 May
MarketsPricesNewsMethodologyB2B platform
Markets/News feed

Peptide R&D news / live registry feed

Fresh peptide-related papers, preprints, clinical-trial registrations, and patent filings from open scientific registries. Every item links back to the originating record; ViraChem doesn’t repost or summarise — we surface and tag.

7d items80All sources
Papers · 7d2Europe PMC
Trials · 7d78CT.gov + EU CTIS
Patents · 7d0USPTO + EPO
Preprints · 7d0bioRxiv · medRxiv
Type ·All 80Paper 2Preprint 0Trial 78Patent 0Window ·7d30d90d

29 May 2026

30 ITEMS
29 MAY02:00 CET
TrialClinicalTrials.gov· NCT04181060PHASE3 · RECRUITING

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is…

National Cancer Institute (NCI)
ClinicalTrials.gov
29 MAY02:00 CET
TrialClinicalTrials.gov· NCT06997497PHASE3 · RECRUITING

A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

Researchers are looking for other ways to treat locally advanced or metastatic colorectal cancer (mCRC) that is unresectable and has a gene mutation called KRAS G12C. Standard (or usual) treatments for this type of colorectal cancer may include mFOLFOX6 with or without bevaciz…

Merck Sharp & Dohme LLC
ClinicalTrials.gov
29 MAY02:00 CET
TrialClinicalTrials.gov· NCT02257528PHASE2 · ACTIVE_NOT_RECRUITING

Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer

This phase II trial studies the side effects and how well nivolumab works in treating patients with cervical cancer that has grown, come back, or spread to other places in the body. Monoclonal antibodies, such as nivolumab, may block tumor growth in different ways by targeting…

National Cancer Institute (NCI)
ClinicalTrials.gov
29 MAY02:00 CET
TrialClinicalTrials.gov· NCT02834013PHASE2 · ACTIVE_NOT_RECRUITING

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

This phase II trial studies nivolumab and ipilimumab in treating patients with rare tumors. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to gro…

National Cancer Institute (NCI)
ClinicalTrials.gov
29 MAY02:00 CET
TrialClinicalTrials.gov· NCT07541209PHASE1PHASE2 · RECRUITING

Safety and Efficacy of PTH-IA

Jansen s Metaphyseal Chondrodysplasia (JMC) is a very rare disorder with only approximately 30 people known to have the disease worldwide. It is caused by parathyroid hormone 1 receptor (PTH1R) variants leading to constitutive activation of the receptor for parathyroid hormone…

National Institute of Dental and Craniofacial Research (NIDCR)
ClinicalTrials.gov
29 MAY02:00 CET
TrialClinicalTrials.gov· NCT01134614PHASE2 · ACTIVE_NOT_RECRUITING

Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

This randomized phase II trial is studying how well giving ipilimumab with or without sargramostim (GM-CSF) works in treating patients with stage III or stage IV melanoma that cannot be removed by surgery (unresectable). Ipilimumab works by activating the patient's immune syst…

National Cancer Institute (NCI)
ClinicalTrials.gov
29 MAY02:00 CET
TrialClinicalTrials.gov· NCT05675410PHASE3 · RECRUITING

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stage I and II classical Hodgkin lymphoma.…

National Cancer Institute (NCI)
ClinicalTrials.gov
29 MAY02:00 CET
TrialClinicalTrials.gov· NCT03984448PHASE2PHASE3 · ACTIVE_NOT_RECRUITING

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas

This phase II/III trial tests whether it is possible to decrease the chance of high-grade B-cell lymphomas returning or getting worse by adding a new drug, venetoclax to the usual combination of drugs used for treatment. Venetoclax may stop the growth of cancer cells by blocki…

National Cancer Institute (NCI)
ClinicalTrials.gov
29 MAY02:00 CET
TrialClinicalTrials.gov· NCT02194738NA · ACTIVE_NOT_RECRUITING

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

This ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain…

National Cancer Institute (NCI)
ClinicalTrials.gov
29 MAY02:00 CET
TrialClinicalTrials.gov· NCT06694454PHASE1PHASE2 · RECRUITING

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Background: Lung cancer is the leading cause of cancer-related death worldwide. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Surgery to remove the tumors is the standard treatment for people diagnosed with early stages of NSCLC. Despite complete r…

National Cancer Institute (NCI)
ClinicalTrials.gov
29 MAY02:00 CET
TrialClinicalTrials.gov· NCT03899402PHASE2PHASE3 · ACTIVE_NOT_RECRUITING

Triple Therapy in T1DM

To assess whether the addition of dapagliflozin to semaglutide and insulin (triple therapy) improves glycemic control in patients with type 1 diabetes compared with semaglutide and insulin (dual therapy) and insulin only (standard) treatment.

State University of New York at Buffalo
ClinicalTrials.gov
29 MAY02:00 CET
TrialClinicalTrials.gov· NCT04983030PHASE1PHASE2 · COMPLETED

Safety, Immunogenicity, Efficacy of Ad26.Mos4.HIV, MVA-BN-HIV and PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected Adults

A multicenter, randomized, parallel-group, placebo-controlled, double-blind, Phase 1/2a clinical study to investigate the safety, tolerability, immunogenicity and exploratory efficacy of a vaccine regimen consisting of an Ad26.Mos4.HIV prime and a boost with Modified Vaccinia …

Boris Juelg, MD PhD
ClinicalTrials.gov
29 MAY02:00 CET
TrialClinicalTrials.gov· NCT03055013PHASE3 · ACTIVE_NOT_RECRUITING

Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy

This phase III trial compares nephrectomy (surgery to remove a kidney or part of a kidney) with nivolumab to the usual approach of nephrectomy followed by standard post-operative follow-up and monitoring, in treating patients with kidney cancer that is limited to a certain par…

National Cancer Institute (NCI)
ClinicalTrials.gov
29 MAY02:00 CET
TrialClinicalTrials.gov· NCT04216342PHASE1 · RECRUITING

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Fx-5A in Healthy Volunteers

Background: Heart disease is the leading cause of death, disability, and healthcare expense in the United States. Researchers think a new drug called Fx-5A may be useful to treat different cardiovascular diseases and inflammation. Objective: To understand the safety, tolerabil…

National Heart, Lung, and Blood Institute (NHLBI)
ClinicalTrials.gov
29 MAY02:00 CET
TrialClinicalTrials.gov· NCT07612631EARLY_PHASE1 · RECRUITING

Imaging CRF X NOP Interactions in Alcohol Use Disorder

This positron emission tomography imaging study uses \[C-11\]NOP-1A and hydrocortisone to image stress-modulating proteins in heavy drinking alcohol use disorder (AUD) subjects and healthy controls (HC). It will also characterize the role of these stress-regulating proteins in…

Rajesh Narendran
ClinicalTrials.gov
29 MAY02:00 CET
TrialClinicalTrials.gov· NCT03793166PHASE3 · ACTIVE_NOT_RECRUITING

Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

This phase III trial compares the usual treatment (treatment with ipilimumab and nivolumab followed by nivolumab alone) to treatment with ipilimumab and nivolumab, followed by nivolumab with cabozantinib in patients with untreated renal cell carcinoma that has spread to other …

National Cancer Institute (NCI)
ClinicalTrials.gov
29 MAY02:00 CET
TrialClinicalTrials.gov· NCT07492680PHASE2 · NOT_YET_RECRUITING

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

This is an open-label, multicenter Phase 2 study evaluating BMS-986504 in participants with advanced and/or metastatic solid tumors that have MTAP deletion. The study includes a monotherapy component and a combination component in which BMS-986504 is given with other anti-canc…

Bristol-Myers Squibb
ClinicalTrials.gov
29 MAY02:00 CET
TrialClinicalTrials.gov· NCT07114601PHASE1 · RECRUITING

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

The main purpose of this study is to evaluate safety, tolerability, and efficacy of LY4257496 alone and as part of relevant standard of care (SOC) combination therapy in participants with Gastrin-releasing Peptide Receptor (GRPR)-positive advanced cancer, including but not lim…

Eli Lilly and Company
ClinicalTrials.gov
29 MAY02:00 CET
TrialClinicalTrials.gov· NCT02224781PHASE3 · ACTIVE_NOT_RECRUITING

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

This phase III trial studies how well initial treatment with ipilimumab and nivolumab followed by dabrafenib and trametinib works and compares it to initial treatment with dabrafenib and trametinib followed by ipilimumab and nivolumab in treating patients with stage III-IV mel…

National Cancer Institute (NCI)
ClinicalTrials.gov
29 MAY02:00 CET
TrialClinicalTrials.gov· NCT05797246PHASE2 · ACTIVE_NOT_RECRUITING

Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)

Background: Recurrent respiratory papillomatosis (RRP) is a rare disease that causes wart-like growths in the airways. These growths come back when removed; some people may need 2 or more surgeries per year to keep their airways clear. Better treatments are needed. Objective: …

National Cancer Institute (NCI)
ClinicalTrials.gov
29 MAY02:00 CET
TrialClinicalTrials.gov· NCT03910452EARLY_PHASE1 · ACTIVE_NOT_RECRUITING

Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide

Background: CGD causes infections and inflammation. The only cure currently is a bone marrow transplant. Most often a perfectly matched bone marrow donor is used. Researchers want to see if they can lower the risks of using a mismatched donor. Objectives: To see if it is safe …

National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov
29 MAY02:00 CET
TrialClinicalTrials.gov· NCT03937830PHASE2 · ACTIVE_NOT_RECRUITING

Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma

Background: Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world. Most people with advanced HCC survive an average of 6 to 9 months. Researchers are evaluating a combination of treatment drugs to delay the progression of HCC; aiming to help people with H…

National Cancer Institute (NCI)
ClinicalTrials.gov
29 MAY02:00 CET
TrialClinicalTrials.gov· NCT05743244PHASE2 · ACTIVE_NOT_RECRUITING

Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)

A multi-center, placebo-controlled, double blind, 1:1:1 randomized control clinical trial testing two different JAK Inhibitors abrocitnib, ritlecitinib, and placebo in subjects with recent onset Stage 3 Type 1 Diabetes within 100 days of diagnosis.

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
ClinicalTrials.gov
29 MAY02:00 CET
TrialClinicalTrials.gov· NCT00663611PHASE1 · COMPLETED

Growth Hormone Administration and the Human Immune System

Background: \- In elderly individuals, an age-associated decline in the immune system s ability to function is believed to contribute to increased incidence of infection, autoimmune disorders, and cancer. This decline in immune system function may be related to the decline in …

National Institute on Aging (NIA)
ClinicalTrials.gov
29 MAY02:00 CET
TrialClinicalTrials.gov· NCT02693535PHASE2 · RECRUITING

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms sec…

American Society of Clinical Oncology
ClinicalTrials.gov
29 MAY02:00 CET
TrialClinicalTrials.gov· NCT07599176PHASE1PHASE2 · RECRUITING

Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors

This is a non-ablative (partial) stem cell transplant for patients with severe sickle cell disease or beta-thalassemia requiring red cell transfusions. The intensity of the transplant is slightly increased from our previous transplant regimens. The goal is to aim for higher pe…

National Heart, Lung, and Blood Institute (NHLBI)
ClinicalTrials.gov
29 MAY02:00 CET
TrialClinicalTrials.gov· NCT05139017PHASE2PHASE3 · RECRUITING

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

The purpose of this Phase 2/3, randomized, multisite, open-label, dose confirmation, and expansion study is to evaluate the safety, and efficacy of zilovertamab vedotin (ZV) in combination with standard of care options for the treatment of rrDLBCL. This study will be divided i…

Merck Sharp & Dohme LLC
ClinicalTrials.gov
29 MAY02:00 CET
TrialClinicalTrials.gov· NCT04267848PHASE3 · RECRUITING

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, ma…

National Cancer Institute (NCI)
ClinicalTrials.gov
29 MAY02:00 CET
TrialClinicalTrials.gov· NCT03842228PHASE1 · ACTIVE_NOT_RECRUITING

Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations

This phase Ib trial seeks to identify the side effects and best dose of the combination of copanlisib and olaparib when given together with durvalumab. The trial will evaluate how well the drug combinations work in treating patients with advanced cancers who have solid tumors …

National Cancer Institute (NCI)
ClinicalTrials.gov
29 MAY02:00 CET
TrialClinicalTrials.gov· NCT01861106PHASE2 · RECRUITING

Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations

Background: \- GATA2 deficiency is a disease caused by mutations in the GATA2 gene. It can cause different types of leukemia and other diseases. Researchers want to see if a stem cell transplant can be used to treat this condition. A stem cell transplant will give stem cells f…

National Cancer Institute (NCI)
ClinicalTrials.gov

28 May 2026

28 ITEMS
28 MAY02:00 CET
PaperEurope PMC· 10.1021/acs.joc.6c00330

Expedient Synthesis of Difficult Proteins via Fmoc Chemistry by Embedding 2-(2-Hydroxyphenyl)thiazolidine Dipeptides (HTDs) as Aggregation Disruptors

Although the chemical protein synthesis offers an effective method for access to customized proteins and their derivatives, the synthesis of water-insoluble polypeptides with difficult sequences is still challenging for conventional solid-phase peptide synthesis (SPPS) and res…

Zhang S, Wang X, Song K, Sui H, Li C, Jin K.
Europe PMC
28 MAY02:00 CET
TrialClinicalTrials.gov· NCT06136897PHASE2 · ACTIVE_NOT_RECRUITING

Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)

This phase II MATCH treatment trial tests how well trastuzumab and pertuzumab work in treating patients with HER2-amplified non-breast, non-gastric/gastroesophageal junction, and non-colorectal cancers. Pertuzumab and trastuzumab are monoclonal antibodies and forms of targeted…

National Cancer Institute (NCI)
ClinicalTrials.gov
28 MAY02:00 CET
TrialClinicalTrials.gov· NCT03560960EARLY_PHASE1 · ACTIVE_NOT_RECRUITING

Multi-Center Development of a Novel Diagnostic Test for Alzheimer's Disease

In this multi-center study, the investigators plan to develop a simple blood-based test for early detection of Alzheimer's disease (AD). The test is based on a single injection of Pramlintide, an amylin analogue and FDA-approved drug currently used for treatment of diabetes. T…

Boston University
ClinicalTrials.gov
28 MAY02:00 CET
TrialClinicalTrials.gov· NCT03219450PHASE1 · RECRUITING

A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.

This research study is studying a novel type of CLL vaccine as a possible treatment for chronic lymphocytic leukemia (CLL) The names of the study interventions involved in this study are: * Personalized NeoAntigen Vaccine * Poly-ICLC * Cyclophosphamide * Pembrolizumab

Dana-Farber Cancer Institute
ClinicalTrials.gov
28 MAY02:00 CET
TrialClinicalTrials.gov· NCT04816643PHASE3 · COMPLETED

Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children

This is a Phase 1/2/3 study in healthy children. Dependent upon safety and/or immunogenicity data generated during the course of this study, and the resulting assessment of benefit-risk, the safety, tolerability, and immunogenicity of BNT162b2 in participants \<6 months of age…

BioNTech SE
ClinicalTrials.gov
28 MAY02:00 CET
TrialClinicalTrials.gov· NCT07611825PHASE2 · NOT_YET_RECRUITING

Gut Microbiota Modulation for Immunotherapy Resensitization in Advanced Renal Cell Carcinoma

The combination of immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) has significantly improved clinical outcomes in patients with advanced renal cell carcinoma (RCC). However, 40%-60% of patients still develop primary or acquired resistance. For those …

Jinling Hospital, China
ClinicalTrials.gov
28 MAY02:00 CET
TrialClinicalTrials.gov· NCT05748990NA · RECRUITING

Does Abnormal Insulin Action in the Brain Underlie Cognitive and Metabolic Dysfunction in Schizophrenia

Cognitive impairment (such as challenges in thinking and memory) is a core aspect of schizophrenia (SCZ), contributing to disability and poor functional outcomes. Additionally, almost half of the patients with SCZ are obese, the prevalence of type 2 diabetes is 3-6 times highe…

Centre for Addiction and Mental Health
ClinicalTrials.gov
28 MAY02:00 CET
TrialClinicalTrials.gov· NCT06508463PHASE1 · RECRUITING

Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma

This phase I trial studies the best dose and side effects of recombinant vesicular stomatitis virus (VSV) carrying the human (h) sodium iodide symporter (NIS) and Interferon (IFN) beta (β) genes (VSV-hIFNβ-NIS) in combination with cemiplimab in patients with T-cell lymphoma. A…

Mayo Clinic
ClinicalTrials.gov
28 MAY02:00 CET
TrialClinicalTrials.gov· NCT02403505PHASE1 · ACTIVE_NOT_RECRUITING

Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating CEA Positive Rectal Cancer

Conducting an early phase clinical trial to assess CEA Antigen Presentation Therapeutic Biological Product Mix activity that suggests the potential for clinical benefit of CEA positive rectal cancer patients. 1. Treat CEA positive rectal cancer via Trained Immunity. 2. Activat…

Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
ClinicalTrials.gov
28 MAY02:00 CET
TrialClinicalTrials.gov· NCT06592261PHASE1 · RECRUITING

Graded Insulin Suppression Test P&F

The goal of this study is to learn about how the hormone insulin controls blood sugar in a variety of people. The main question it aims to answer is about how much insulin the body actually needs to maintain a normal blood sugar level. Participants will be asked to come in for…

Columbia University
ClinicalTrials.gov
28 MAY02:00 CET
TrialClinicalTrials.gov· NCT06333951PHASE1 · ACTIVE_NOT_RECRUITING

Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).

The study aims to determine maximum tolerated dose (MTD) or recommended combination dose of the MTA-cooperative PRMT5 inhibitor Anvumetostat administered in combination with other therapies in adult participants with metastatic or locally advanced methylthioadenosine phosphory…

Amgen
ClinicalTrials.gov
28 MAY02:00 CET
TrialClinicalTrials.gov· NCT03890237NA · ACTIVE_NOT_RECRUITING

GAGE Act With Her-Ethiopia Evaluation

This study evaluates the impact of Act With Her Ethiopia (AWH-E), a gender transformative multi-level program that aims to improve the lives of young adolescent boys and girls.

George Washington University
ClinicalTrials.gov
28 MAY02:00 CET
TrialClinicalTrials.gov· NCT07198074PHASE3 · RECRUITING

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

This phase III trial compares the effect of bevacizumab in combination with carboplatin, paclitaxel and pembrolizumab to the usual treatments of carboplatin and paclitaxel with or without pembrolizumab in treating patients with stage III, IVA or IVB mismatch repair protein pro…

National Cancer Institute (NCI)
ClinicalTrials.gov
28 MAY02:00 CET
TrialClinicalTrials.gov· NCT06485089COMPLETED

Effects of Tirzepatide on Blood, Imaging and Breast Tissue Biomarkers

Evaluation of biomarkers for risk of developing breast cancer in women with obesity who are using tirzepatide to achieve weight loss.

University of Kansas Medical Center
ClinicalTrials.gov
28 MAY02:00 CET
TrialClinicalTrials.gov· NCT04514484PHASE1 · ACTIVE_NOT_RECRUITING

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

This phase I trial investigates the side effects of cabozantinib and nivolumab in treating patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and who are undergoing treatment for human im…

National Cancer Institute (NCI)
ClinicalTrials.gov
28 MAY02:00 CET
TrialClinicalTrials.gov· NCT07610720PHASE2 · RECRUITING

Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer

Efficacy and Safety of Dalpiciclib Combined with Anti-HER2 Targeted Therapy and Endocrine Therapy as First-line Maintenance Treatment for Patients with Recurrent or Metastatic Hormone-Receptor-Positive, HER2-positive Breast Cancer.

Sun Yat-sen University
ClinicalTrials.gov
28 MAY02:00 CET
TrialClinicalTrials.gov· NCT02314169PHASE2 · ACTIVE_NOT_RECRUITING

Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer

This phase II trial studies how well nivolumab with or without ipilimumab works in treating patients with anal canal cancer that has not responded to previous treatment (refractory) and that has spread from where it first started (primary site) to other places in the body (met…

National Cancer Institute (NCI)
ClinicalTrials.gov
28 MAY02:00 CET
TrialClinicalTrials.gov· NCT07221357PHASE2PHASE3 · RECRUITING

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

The purpose of this study is to evaluate the safety and efficacy of pumitamig in combination with chemotherapy versus bevacizumab in combination with chemotherapy in participants with previously untreated, unresectable, or metastatic colorectal cancer

Bristol-Myers Squibb
ClinicalTrials.gov
28 MAY02:00 CET
TrialClinicalTrials.gov· NCT06161441PHASE2 · ACTIVE_NOT_RECRUITING

A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery

This study is researching an experimental drug called fianlimab (also called REGN3767) with two other medications called cemiplimab and platinum-doublet chemotherapy, individually called a "study drug" or collectively called "study drugs", when combined in this study. The stud…

Regeneron Pharmaceuticals
ClinicalTrials.gov
28 MAY02:00 CET
TrialClinicalTrials.gov· NCT05987241PHASE2PHASE3 · RECRUITING

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

This phase II/III trial examines whether patients who have undergone surgical removal of bladder, kidney, ureter or urethra, but require an additional treatment called immunotherapy to help prevent their urinary tract (urothelial) cancer from coming back, can be identified by …

National Cancer Institute (NCI)
ClinicalTrials.gov
28 MAY02:00 CET
TrialClinicalTrials.gov· NCT07404332PHASE1 · RECRUITING

5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors

This is a Phase I study to determine the optimal biological dose (OBD) of 5-Azacitidine in combination with PD-1/PD-L1 inhibitors in patients with tumors refractory to PD-1/PD-L1 inhibitors, for which such treatments have been approved.

Mohammed Milhem
ClinicalTrials.gov
28 MAY02:00 CET
TrialClinicalTrials.gov· NCT07611305NA · NOT_YET_RECRUITING

ProGo Menopause Wellbeing Study

This study will evaluate whether ProGo®, a salmon protein hydrolysate (SPH), helps to moderate BMI and improve quality of life (QoL) in menopausal women. Healthy, overweight (BMI 25-32.5) menopausal women aged 40-65 years with will be enrolled and participants will be randomiz…

Hofseth Biocare ASA
ClinicalTrials.gov
28 MAY02:00 CET
TrialClinicalTrials.gov· NCT02506153PHASE3 · ACTIVE_NOT_RECRUITING

Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery

This randomized phase III trial studies how well pembrolizumab works compared with the current standard of care, physician/patient choice of either high-dose recombinant interferon alfa-2B or ipilimumab, in treating patients with stage III-IV melanoma that has been removed by …

National Cancer Institute (NCI)
ClinicalTrials.gov
28 MAY02:00 CET
TrialClinicalTrials.gov· NCT07610616RECRUITING

Study on the Mechanism of ADC Drug Evaluation Based on Immune Co-culture of Lung Cancer Organoids

A case-control study was conducted to evaluate the efficacy and mechanism of action of antibody-drug conjugates (ADCs) in lung cancer, utilizing patient-derived organoid (PDO)-immune co-cultures. Focusing on HER2-positive and TROP2-positive non-small cell lung cancer (NSCLC) c…

Guangzhou Institute of Respiratory Disease
ClinicalTrials.gov
28 MAY02:00 CET
TrialClinicalTrials.gov· NCT04766723PHASE2 · COMPLETED

A Study to Investigate the Efficacy and Safety of NT 201 (Botulinum Toxin) Compared With Placebo for the Treatment of Adult Participants With Essential Tremor in the Arm

The purpose of this study is to determine whether a single treatment with NT 201 (botulinum toxin) is superior to placebo (no medicine) for one-sided treatment of essential tremor in the motor-dominant arm (Unilateral Period). Participants will be assigned to the treatment gro…

Merz Pharmaceuticals GmbH
ClinicalTrials.gov
28 MAY02:00 CET
TrialClinicalTrials.gov· NCT05799521PHASE2 · ACTIVE_NOT_RECRUITING

A Nasal Treatment for COVID-19

The goal of this study is to test an investigational new inhaled medication called Optate.

Indiana University
ClinicalTrials.gov
28 MAY02:00 CET
TrialClinicalTrials.gov· NCT07611058NA · COMPLETED

Inflammatory Response in Children Suffering From Tethered Cord

Embryologic phenomenons that lead to dysraphisms are known, but pathophysiology remains questioned. It is supposed not to be a simple mechanistic dysfunction, and other biological phenomenons are implied in spinal cord damaging. Two main hypothesis are that manual deformation …

University Hospital, Lille
ClinicalTrials.gov
28 MAY02:00 CET
TrialClinicalTrials.gov· NCT07223047PHASE1PHASE2 · RECRUITING

A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

The purpose of this study is to evaluate the safety, tolerability, and efficacy of BMS-986523 alone and in combination with anti-cancer agents in participants with advanced solid malignancies

Bristol-Myers Squibb
ClinicalTrials.gov

27 May 2026

22 ITEMS
27 MAY02:00 CET
PaperEurope PMC· PMC13210295

Let the peptides shine: SOX (Sulfonamido-OXine)-labelled peptides for direct kinase and phosphatase monitoring

Papagora L, Cochrane S.
Europe PMC
27 MAY02:00 CET
TrialClinicalTrials.gov· NCT06172296PHASE3 · RECRUITING

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

This phase III trial tests how well the addition of dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy works for treating children with newly diagnosed high-risk neu…

National Cancer Institute (NCI)
ClinicalTrials.gov
27 MAY02:00 CET
TrialClinicalTrials.gov· NCT05564377PHASE2 · RECRUITING

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or have spread to other places i…

National Cancer Institute (NCI)
ClinicalTrials.gov
27 MAY02:00 CET
TrialClinicalTrials.gov· NCT04126070PHASE2 · ACTIVE_NOT_RECRUITING

Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors

This research study is studying a combination of hormonal therapy, chemotherapy, and immunotherapy as a possible treatment for metastatic hormone-sensitive prostate cancer. The names of the study drugs involved in this study are: * Androgen deprivation therapy (ADT) with a dru…

Xiao X. Wei, MD
ClinicalTrials.gov
27 MAY02:00 CET
TrialClinicalTrials.gov· NCT07179380PHASE3 · RECRUITING

Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

The primary objective of this study is to evaluate the effect of 24-weeks of once daily treatment with TPIP versus placebo on exercise capacity in adults with PH-ILD.

Insmed Incorporated
ClinicalTrials.gov
27 MAY02:00 CET
TrialClinicalTrials.gov· NCT05823727NA · RECRUITING

Effects of Collagen Peptide Supplementation on Connective Tissue Remodeling, Functional Outcomes, and Wound Healing After Total Knee Arthroplasty (TKA)

Recruiting will be performed via checking the calendar for scheduled TKA procedures in the \> 8 weeks by clinical staff in the UAMS orthopedic clinic. Clinic staff will look for basic inclusion/exclusion criteria in the EMR for those patients. Clinic staff will either contact …

University of Arkansas
ClinicalTrials.gov
27 MAY02:00 CET
TrialClinicalTrials.gov· NCT07361302PHASE3 · RECRUITING

A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well

This study is open to adults who had an acute stroke caused by a clot blocking a blood vessel in the brain (acute ischemic stroke). This study is for people who had an acute stroke or woke up with a stroke and were last seen well more than 4.5 hours before joining the study. P…

Boehringer Ingelheim
ClinicalTrials.gov
27 MAY02:00 CET
TrialClinicalTrials.gov· NCT03561649NA · COMPLETED

Prediction of Treatment Response at 6 Months by Combinatorial Analysis of Serum Biomarkers in Biotherapy Naive SpA

The main objective of this trial is to search for biomarkers associated with the success of adalimumab treatment in order to generate an algorithm to predict the response to this treatment at 6 months in spondyloarthritis and to define its metrological properties on this cohor…

University Hospital, Grenoble
ClinicalTrials.gov
27 MAY02:00 CET
TrialClinicalTrials.gov· NCT07608848EARLY_PHASE1 · NOT_YET_RECRUITING

First-in-human Imaging Study of Theranostic Pair [68Ga]Ga-DOTA-STR-17126 and Low-dose [177Lu]Lu-DOTA-STR-17126 in Patients With Advanced or Metastatic Cancer

This is an open-label, first-in-human, exploratory Phase 0 study evaluating the safety and diagnostic imaging performance of the DOTA-STR-17126 theranostic pair in patients with advanced or metastatic breast or prostate cancer. The study investigates \[68Ga\]Ga-DOTA-STR-17126 …

Integrated Haematology and Oncology Network
ClinicalTrials.gov
27 MAY02:00 CET
TrialClinicalTrials.gov· NCT07610213PHASE1 · NOT_YET_RECRUITING

Sequential Immune Modulation and Antigen-Specific Tolerance Induction for Disease Modification in Recent-Onset Type 1 Diabetes

This study tests a three-phase immune treatment for people recently diagnosed with Type 1 diabetes (within 6 months, with some insulin production remaining). Phase 1 (weeks 1-2): Teplizumab, an anti-CD3 antibody, is given by infusion to slow immune attack on insulin-producing …

Abdullah Kars
ClinicalTrials.gov
27 MAY02:00 CET
TrialClinicalTrials.gov· NCT07012044PHASE1 · RECRUITING

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

This phase I trial tests the safety, side effects, and best dose of ASTX727 and filgrastim for the treatment of children with high risk acute myeloid leukemia that has come back after a period of improvement (recurrent) or that does not respond to treatment (refractory) who ha…

National Cancer Institute (NCI)
ClinicalTrials.gov
27 MAY02:00 CET
TrialClinicalTrials.gov· NCT04704934PHASE3 · ACTIVE_NOT_RECRUITING

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

This study will evaluate the efficacy and safety of trastuzumab deruxtecan (T-DXd) compared with ramucirumab and paclitaxel (Ram + PTX) in participants with HER2-positive gastric or gastro-esophageal junction (GEJ) adenocarcinoma who have progressed on or after a trastuzumab-c…

Daiichi Sankyo
ClinicalTrials.gov
27 MAY02:00 CET
TrialClinicalTrials.gov· NCT06820463PHASE2 · RECRUITING

A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

CRC is the third most common type of cancer diagnosed worldwide with developed countries at highest risk. The purpose of this study is to assess adverse events and change in disease activity when telisotuzumab adizutecan is given in combination with oxaliplatin, fluorouracil (…

AbbVie
ClinicalTrials.gov
27 MAY02:00 CET
TrialClinicalTrials.gov· NCT05256225PHASE3 · RECRUITING

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

This phase III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin Hylecta \[TM\]) or pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo \[TM\]) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positiv…

National Cancer Institute (NCI)
ClinicalTrials.gov
27 MAY02:00 CET
TrialClinicalTrials.gov· NCT07116967PHASE3 · RECRUITING

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

A study to evaluate the long-term safety of Deucravacitinib versus Ustekinumab in participants with psoriasis

Bristol-Myers Squibb
ClinicalTrials.gov
27 MAY02:00 CET
TrialClinicalTrials.gov· NCT07207811PHASE3 · RECRUITING

CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

This study will find out if a new medicine called NNC6019-0001 can help reduce the risk of heart-related death and illness in participants with a condition called transthyretin amyloid cardiomyopathy (ATTR-CM), which affects the heart. Participants will either receive NNC6019-…

Novo Nordisk A/S
ClinicalTrials.gov
27 MAY02:00 CET
TrialClinicalTrials.gov· NCT06954805PHASE2 · RECRUITING

Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)

The purpose of this study is to find out if there is a benefit to giving rituximab with etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin (R-EPOCH) in participants who have high-risk B-cell PTLD in their 2nd phase of treatment (consolidation) while those wit…

Jennifer Amengual
ClinicalTrials.gov
27 MAY02:00 CET
TrialClinicalTrials.gov· NCT03120468EARLY_PHASE1 · COMPLETED

Topiramate Augmenting Strategies for the Treatment of Alcohol Use Disorder

This is a pilot study designed to evaluate the safety, tolerability of Topiramate (TPM) + N-Acetyl Cysteine (NAC) in combination versus Topiramate (TPM) + placebo for the treatment of alcohol use disorder (AUD).

Nassima Ait-Daoud Tiouririne
ClinicalTrials.gov
27 MAY02:00 CET
TrialClinicalTrials.gov· NCT06040320PHASE1PHASE2 · RECRUITING

Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)

This study will test polatuzumab vedotin in combination with rituximab in patients with treatment-naïve CD20-positive post-transplant lymphoproliferative disorder (PTLD) based on the established efficacy of polatuzumab vedotin in B-cell lymphomas and the inadequate response ra…

Washington University School of Medicine
ClinicalTrials.gov
27 MAY02:00 CET
TrialClinicalTrials.gov· NCT06533098PHASE3 · RECRUITING

A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

The purpose of this study is to assess the efficacy and safety of nipocalimab in reducing the risk of severe fetal and neonatal alloimmune thrombocytopenia (FNAIT).

Janssen Research & Development, LLC
ClinicalTrials.gov
27 MAY02:00 CET
TrialClinicalTrials.gov· NCT04840602PHASE2 · RECRUITING

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

This phase II trial studies the effects of venetoclax and rituximab in comparison to ibrutinib and rituximab or zanubrutinib in treating patients with previously untreated Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. Ibrutinib may stop the growth of cancer cells…

National Cancer Institute (NCI)
ClinicalTrials.gov
27 MAY02:00 CET
TrialClinicalTrials.gov· NCT00600496PHASE1 · COMPLETED

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

This study is being conducted to determine if a combination of AZD6244 given orally twice a day with standard doses of selected chemotherapies will be safe and tolerable for cancer patients with advanced solid tumors. The highest tolerated dose of AZD6244 in combination with s…

AstraZeneca
ClinicalTrials.gov